Islet Transplantation Using PKX-001

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

February 17, 2017

Primary Completion Date

May 7, 2025

Study Completion Date

May 7, 2025

Conditions
Type 1 Diabetes Mellitus
Interventions
DRUG

Antiaging Glycopeptide

Antiaging Glycopeptide (PKX-001) will be supplemented to islet preservation medium during islet isolation process. On the day of transplantation, preserved islets supplemented with PKX-001 are collected and washed with Transplant Media, which does not contain PKX-001, as a standard procedure. The isolation team will evaluate the final islet product based on standard assays used in standard of care practice. When product release minimal criteria are met, islets will be clinically transplanted into patients intraportally by percutaneous transhepatic access.

Trial Locations (1)

T6G2C8

University of Alberta, Edmonton

All Listed Sponsors
collaborator

ProtoKinetix Inc.

UNKNOWN

lead

University of Alberta

OTHER

NCT03073577 - Islet Transplantation Using PKX-001 | Biotech Hunter | Biotech Hunter